Report cover image

Amyloidosis Therapeutics Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 128 Pages
SKU # APRC20543234

Description

Summary

According to APO Research, the global Amyloidosis Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Amyloidosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyloidosis Therapeutics.

The report will help the Amyloidosis Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Amyloidosis Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyloidosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Amyloidosis Therapeutics Segment by Company
Pfizer Inc. GlaxoSmithKline Plc SOM Innovation Biotech SL Prothena Corporation Plc ProteoTech, Inc. Onyx Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Isis Pharmaceuticals, Inc. Celgene Corporation Bsim2 Bellus Health Inc. Arcturus Therapeutics, Inc Alnylam Pharmaceuticals, Inc.Amyloidosis Therapeutics Segment by Type
Canakinumab CAEL-101 ALN-TTRsc02 ALN-ANG AG-10 OthersAmyloidosis Therapeutics Segment by Application
ATTR Amyloidoses AL Amyloidosis AA Amyloidoses OthersAmyloidosis Therapeutics Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Colombia Middle East & Africa Turkey Saudi Arabia UAE

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Amyloidosis Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Amyloidosis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

128 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Amyloidosis Therapeutics Market Size (2020-2031)
2.2.2 Global Amyloidosis Therapeutics Sales (2020-2031)
2.2.3 Global Amyloidosis Therapeutics Market Average Price (2020-2031)
2.3 Amyloidosis Therapeutics by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Canakinumab
2.3.3 CAEL-101
2.3.4 ALN-TTRsc02
2.3.5 ALN-ANG
2.3.6 AG-10
2.3.7 Others
2.4 Amyloidosis Therapeutics by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 ATTR Amyloidoses
2.4.3 AL Amyloidosis
2.4.4 AA Amyloidoses
2.4.5 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Amyloidosis Therapeutics Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Amyloidosis Therapeutics Sales (k units) of Manufacturers (2020-2025)
3.3 Global Amyloidosis Therapeutics Revenue of Manufacturers (2020-2025)
3.4 Global Amyloidosis Therapeutics Average Price by Manufacturers (2020-2025)
3.5 Global Amyloidosis Therapeutics Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Amyloidosis Therapeutics, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Amyloidosis Therapeutics, Product Type & Application
3.8 Global Manufacturers of Amyloidosis Therapeutics, Established Date
3.9 Global Amyloidosis Therapeutics Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Pfizer Inc.
4.1.1 Pfizer Inc. Company Information
4.1.2 Pfizer Inc. Business Overview
4.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
4.1.5 Pfizer Inc. Recent Developments
4.2 GlaxoSmithKline Plc
4.2.1 GlaxoSmithKline Plc Company Information
4.2.2 GlaxoSmithKline Plc Business Overview
4.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
4.2.5 GlaxoSmithKline Plc Recent Developments
4.3 SOM Innovation Biotech SL
4.3.1 SOM Innovation Biotech SL Company Information
4.3.2 SOM Innovation Biotech SL Business Overview
4.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
4.3.5 SOM Innovation Biotech SL Recent Developments
4.4 Prothena Corporation Plc
4.4.1 Prothena Corporation Plc Company Information
4.4.2 Prothena Corporation Plc Business Overview
4.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
4.4.5 Prothena Corporation Plc Recent Developments
4.5 ProteoTech, Inc.
4.5.1 ProteoTech, Inc. Company Information
4.5.2 ProteoTech, Inc. Business Overview
4.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
4.5.5 ProteoTech, Inc. Recent Developments
4.6 Onyx Pharmaceuticals, Inc.
4.6.1 Onyx Pharmaceuticals, Inc. Company Information
4.6.2 Onyx Pharmaceuticals, Inc. Business Overview
4.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
4.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
4.7 Millennium Pharmaceuticals, Inc.
4.7.1 Millennium Pharmaceuticals, Inc. Company Information
4.7.2 Millennium Pharmaceuticals, Inc. Business Overview
4.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
4.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
4.8 Isis Pharmaceuticals, Inc.
4.8.1 Isis Pharmaceuticals, Inc. Company Information
4.8.2 Isis Pharmaceuticals, Inc. Business Overview
4.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
4.8.5 Isis Pharmaceuticals, Inc. Recent Developments
4.9 Celgene Corporation
4.9.1 Celgene Corporation Company Information
4.9.2 Celgene Corporation Business Overview
4.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
4.9.5 Celgene Corporation Recent Developments
4.10 Bsim2
4.10.1 Bsim2 Company Information
4.10.2 Bsim2 Business Overview
4.10.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
4.10.5 Bsim2 Recent Developments
4.11 Bellus Health Inc.
4.11.1 Bellus Health Inc. Company Information
4.11.2 Bellus Health Inc. Business Overview
4.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
4.11.5 Bellus Health Inc. Recent Developments
4.12 Arcturus Therapeutics, Inc
4.12.1 Arcturus Therapeutics, Inc Company Information
4.12.2 Arcturus Therapeutics, Inc Business Overview
4.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
4.12.5 Arcturus Therapeutics, Inc Recent Developments
4.13 Alnylam Pharmaceuticals, Inc.
4.13.1 Alnylam Pharmaceuticals, Inc. Company Information
4.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
4.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
4.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
5 Global Amyloidosis Therapeutics Market Scenario by Region
5.1 Global Amyloidosis Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Amyloidosis Therapeutics Sales by Region: 2020-2031
5.2.1 Global Amyloidosis Therapeutics Sales by Region: 2020-2025
5.2.2 Global Amyloidosis Therapeutics Sales by Region: 2026-2031
5.3 Global Amyloidosis Therapeutics Revenue by Region: 2020-2031
5.3.1 Global Amyloidosis Therapeutics Revenue by Region: 2020-2025
5.3.2 Global Amyloidosis Therapeutics Revenue by Region: 2026-2031
5.4 North America Amyloidosis Therapeutics Market Facts & Figures by Country
5.4.1 North America Amyloidosis Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Amyloidosis Therapeutics Sales by Country (2020-2031)
5.4.3 North America Amyloidosis Therapeutics Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Amyloidosis Therapeutics Market Facts & Figures by Country
5.5.1 Europe Amyloidosis Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Amyloidosis Therapeutics Sales by Country (2020-2031)
5.5.3 Europe Amyloidosis Therapeutics Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Amyloidosis Therapeutics Market Facts & Figures by Country
5.6.1 Asia Pacific Amyloidosis Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Amyloidosis Therapeutics Sales by Country (2020-2031)
5.6.3 Asia Pacific Amyloidosis Therapeutics Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Amyloidosis Therapeutics Market Facts & Figures by Country
5.7.1 South America Amyloidosis Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Amyloidosis Therapeutics Sales by Country (2020-2031)
5.7.3 South America Amyloidosis Therapeutics Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Amyloidosis Therapeutics Market Facts & Figures by Country
5.8.1 Middle East and Africa Amyloidosis Therapeutics Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Amyloidosis Therapeutics Sales by Country (2020-2031)
5.8.3 Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Amyloidosis Therapeutics Sales by Type (2020-2031)
6.1.1 Global Amyloidosis Therapeutics Sales by Type (2020-2031) & (k units)
6.1.2 Global Amyloidosis Therapeutics Sales Market Share by Type (2020-2031)
6.2 Global Amyloidosis Therapeutics Revenue by Type (2020-2031)
6.2.1 Global Amyloidosis Therapeutics Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Amyloidosis Therapeutics Revenue Market Share by Type (2020-2031)
6.3 Global Amyloidosis Therapeutics Price by Type (2020-2031)
7 Segment by Application
7.1 Global Amyloidosis Therapeutics Sales by Application (2020-2031)
7.1.1 Global Amyloidosis Therapeutics Sales by Application (2020-2031) & (k units)
7.1.2 Global Amyloidosis Therapeutics Sales Market Share by Application (2020-2031)
7.2 Global Amyloidosis Therapeutics Revenue by Application (2020-2031)
7.2.1 Global Amyloidosis Therapeutics Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Amyloidosis Therapeutics Revenue Market Share by Application (2020-2031)
7.3 Global Amyloidosis Therapeutics Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Amyloidosis Therapeutics Value Chain Analysis
8.1.1 Amyloidosis Therapeutics Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Amyloidosis Therapeutics Production Mode & Process
8.2 Amyloidosis Therapeutics Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Amyloidosis Therapeutics Distributors
8.2.3 Amyloidosis Therapeutics Customers
9 Global Amyloidosis Therapeutics Analyzing Market Dynamics
9.1 Amyloidosis Therapeutics Industry Trends
9.2 Amyloidosis Therapeutics Industry Drivers
9.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
9.4 Amyloidosis Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Amyloidosis Therapeutics Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global Amyloidosis Therapeutics Sales (k units) of Manufacturers (2020-2025)
Table 7. Global Amyloidosis Therapeutics Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Amyloidosis Therapeutics Revenue of Manufacturers (2020-2025)
Table 9. Global Amyloidosis Therapeutics Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market Amyloidosis Therapeutics Average Price (US$/unit) of Manufacturers (2020-2025)
Table 11. Global Amyloidosis Therapeutics Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of Amyloidosis Therapeutics, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Amyloidosis Therapeutics, Product Type & Application
Table 14. Global Amyloidosis Therapeutics Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Amyloidosis Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Pfizer Inc. Company Information
Table 19. Pfizer Inc. Business Overview
Table 20. Pfizer Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 21. Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
Table 22. Pfizer Inc. Recent Developments
Table 23. GlaxoSmithKline Plc Company Information
Table 24. GlaxoSmithKline Plc Business Overview
Table 25. GlaxoSmithKline Plc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 26. GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
Table 27. GlaxoSmithKline Plc Recent Developments
Table 28. SOM Innovation Biotech SL Company Information
Table 29. SOM Innovation Biotech SL Business Overview
Table 30. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 31. SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
Table 32. SOM Innovation Biotech SL Recent Developments
Table 33. Prothena Corporation Plc Company Information
Table 34. Prothena Corporation Plc Business Overview
Table 35. Prothena Corporation Plc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 36. Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
Table 37. Prothena Corporation Plc Recent Developments
Table 38. ProteoTech, Inc. Company Information
Table 39. ProteoTech, Inc. Business Overview
Table 40. ProteoTech, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 41. ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
Table 42. ProteoTech, Inc. Recent Developments
Table 43. Onyx Pharmaceuticals, Inc. Company Information
Table 44. Onyx Pharmaceuticals, Inc. Business Overview
Table 45. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 46. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
Table 47. Onyx Pharmaceuticals, Inc. Recent Developments
Table 48. Millennium Pharmaceuticals, Inc. Company Information
Table 49. Millennium Pharmaceuticals, Inc. Business Overview
Table 50. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 51. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
Table 52. Millennium Pharmaceuticals, Inc. Recent Developments
Table 53. Isis Pharmaceuticals, Inc. Company Information
Table 54. Isis Pharmaceuticals, Inc. Business Overview
Table 55. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 56. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
Table 57. Isis Pharmaceuticals, Inc. Recent Developments
Table 58. Celgene Corporation Company Information
Table 59. Celgene Corporation Business Overview
Table 60. Celgene Corporation Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 61. Celgene Corporation Amyloidosis Therapeutics Product Portfolio
Table 62. Celgene Corporation Recent Developments
Table 63. Bsim2 Company Information
Table 64. Bsim2 Business Overview
Table 65. Bsim2 Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 66. Bsim2 Amyloidosis Therapeutics Product Portfolio
Table 67. Bsim2 Recent Developments
Table 68. Bellus Health Inc. Company Information
Table 69. Bellus Health Inc. Business Overview
Table 70. Bellus Health Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 71. Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
Table 72. Bellus Health Inc. Recent Developments
Table 73. Arcturus Therapeutics, Inc Company Information
Table 74. Arcturus Therapeutics, Inc Business Overview
Table 75. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 76. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
Table 77. Arcturus Therapeutics, Inc Recent Developments
Table 78. Alnylam Pharmaceuticals, Inc. Company Information
Table 79. Alnylam Pharmaceuticals, Inc. Business Overview
Table 80. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 81. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
Table 82. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 83. Global Amyloidosis Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 84. Global Amyloidosis Therapeutics Sales by Region (2020-2025) & (k units)
Table 85. Global Amyloidosis Therapeutics Sales Market Share by Region (2020-2025)
Table 86. Global Amyloidosis Therapeutics Sales by Region (2026-2031) & (k units)
Table 87. Global Amyloidosis Therapeutics Sales Market Share by Region (2026-2031)
Table 88. Global Amyloidosis Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 89. Global Amyloidosis Therapeutics Revenue Market Share by Region (2020-2025)
Table 90. Global Amyloidosis Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 91. Global Amyloidosis Therapeutics Revenue Market Share by Region (2026-2031)
Table 92. North America Amyloidosis Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 93. North America Amyloidosis Therapeutics Sales by Country (2020-2025) & (k units)
Table 94. North America Amyloidosis Therapeutics Sales by Country (2026-2031) & (k units)
Table 95. North America Amyloidosis Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 96. North America Amyloidosis Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 97. Europe Amyloidosis Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 98. Europe Amyloidosis Therapeutics Sales by Country (2020-2025) & (k units)
Table 99. Europe Amyloidosis Therapeutics Sales by Country (2026-2031) & (k units)
Table 100. Europe Amyloidosis Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 101. Europe Amyloidosis Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 102. Asia Pacific Amyloidosis Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 103. Asia Pacific Amyloidosis Therapeutics Sales by Country (2020-2025) & (k units)
Table 104. Asia Pacific Amyloidosis Therapeutics Sales by Country (2026-2031) & (k units)
Table 105. Asia Pacific Amyloidosis Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 106. Asia Pacific Amyloidosis Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 107. South America Amyloidosis Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 108. South America Amyloidosis Therapeutics Sales by Country (2020-2025) & (k units)
Table 109. South America Amyloidosis Therapeutics Sales by Country (2026-2031) & (k units)
Table 110. South America Amyloidosis Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 111. South America Amyloidosis Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 112. Middle East and Africa Amyloidosis Therapeutics Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 113. Middle East and Africa Amyloidosis Therapeutics Sales by Country (2020-2025) & (k units)
Table 114. Middle East and Africa Amyloidosis Therapeutics Sales by Country (2026-2031) & (k units)
Table 115. Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 116. Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 117. Global Amyloidosis Therapeutics Sales by Type (2020-2025) & (k units)
Table 118. Global Amyloidosis Therapeutics Sales by Type (2026-2031) & (k units)
Table 119. Global Amyloidosis Therapeutics Sales Market Share by Type (2020-2025)
Table 120. Global Amyloidosis Therapeutics Sales Market Share by Type (2026-2031)
Table 121. Global Amyloidosis Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 122. Global Amyloidosis Therapeutics Revenue by Type (2026-2031) & (US$ Million)
Table 123. Global Amyloidosis Therapeutics Revenue Market Share by Type (2020-2025)
Table 124. Global Amyloidosis Therapeutics Revenue Market Share by Type (2026-2031)
Table 125. Global Amyloidosis Therapeutics Price by Type (2020-2025) & (US$/unit)
Table 126. Global Amyloidosis Therapeutics Price by Type (2026-2031) & (US$/unit)
Table 127. Global Amyloidosis Therapeutics Sales by Application (2020-2025) & (k units)
Table 128. Global Amyloidosis Therapeutics Sales by Application (2026-2031) & (k units)
Table 129. Global Amyloidosis Therapeutics Sales Market Share by Application (2020-2025)
Table 130. Global Amyloidosis Therapeutics Sales Market Share by Application (2026-2031)
Table 131. Global Amyloidosis Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 132. Global Amyloidosis Therapeutics Revenue by Application (2026-2031) & (US$ Million)
Table 133. Global Amyloidosis Therapeutics Revenue Market Share by Application (2020-2025)
Table 134. Global Amyloidosis Therapeutics Revenue Market Share by Application (2026-2031)
Table 135. Global Amyloidosis Therapeutics Price by Application (2020-2025) & (US$/unit)
Table 136. Global Amyloidosis Therapeutics Price by Application (2026-2031) & (US$/unit)
Table 137. Key Raw Materials
Table 138. Raw Materials Key Suppliers
Table 139. Amyloidosis Therapeutics Distributors List
Table 140. Amyloidosis Therapeutics Customers List
Table 141. Amyloidosis Therapeutics Industry Trends
Table 142. Amyloidosis Therapeutics Industry Drivers
Table 143. Amyloidosis Therapeutics Industry Restraints
Table 144. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Amyloidosis Therapeutics Product Image
Figure 5. Global Amyloidosis Therapeutics Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global Amyloidosis Therapeutics Market Size (2020-2031) & (US$ Million)
Figure 7. Global Amyloidosis Therapeutics Sales (2020-2031) & (k units)
Figure 8. Global Amyloidosis Therapeutics Average Price (US$/unit) & (2020-2031)
Figure 9. Canakinumab Product Image
Figure 10. CAEL-101 Product Image
Figure 11. ALN-TTRsc02 Product Image
Figure 12. ALN-ANG Product Image
Figure 13. AG-10 Product Image
Figure 14. Others Product Image
Figure 15. ATTR Amyloidoses Product Image
Figure 16. AL Amyloidosis Product Image
Figure 17. AA Amyloidoses Product Image
Figure 18. Others Product Image
Figure 19. Global Amyloidosis Therapeutics Revenue Share by Manufacturers in 2024
Figure 20. Global Manufacturers of Amyloidosis Therapeutics, Manufacturing Sites & Headquarters
Figure 21. Global Top 5 and 10 Amyloidosis Therapeutics Players Market Share by Revenue in 2024
Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Amyloidosis Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. Global Amyloidosis Therapeutics Sales by Region in 2024
Figure 25. Global Amyloidosis Therapeutics Revenue by Region in 2024
Figure 26. North America Amyloidosis Therapeutics Market Size by Country in 2024
Figure 27. North America Amyloidosis Therapeutics Sales Market Share by Country (2020-2031)
Figure 28. North America Amyloidosis Therapeutics Revenue Market Share by Country (2020-2031)
Figure 29. United States Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Canada Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Europe Amyloidosis Therapeutics Market Size by Country in 2024
Figure 32. Europe Amyloidosis Therapeutics Sales Market Share by Country (2020-2031)
Figure 33. Europe Amyloidosis Therapeutics Revenue Market Share by Country (2020-2031)
Figure 34. Germany Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. France Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. U.K. Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Italy Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Netherlands Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Asia Pacific Amyloidosis Therapeutics Market Size by Country in 2024
Figure 40. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Country (2020-2031)
Figure 41. Asia Pacific Amyloidosis Therapeutics Revenue Market Share by Country (2020-2031)
Figure 42. China Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Japan Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. South Korea Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. India Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Australia Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. China Taiwan Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Southeast Asia Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Southeast Asia Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. South America Amyloidosis Therapeutics Market Size by Country in 2024
Figure 51. South America Amyloidosis Therapeutics Sales Market Share by Country (2020-2031)
Figure 52. South America Amyloidosis Therapeutics Revenue Market Share by Country (2020-2031)
Figure 53. Mexico Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Brazil Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Argentina Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Colombia Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Amyloidosis Therapeutics Market Size by Country in 2024
Figure 58. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Country (2020-2031)
Figure 59. Middle East and Africa Amyloidosis Therapeutics Revenue Market Share by Country (2020-2031)
Figure 60. Turkey Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 61. Saudi Arabia Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 62. UAE Amyloidosis Therapeutics Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 63. Global Amyloidosis Therapeutics Sales Market Share by Type (2020-2031)
Figure 64. Global Amyloidosis Therapeutics Revenue Market Share by Type (2020-2031)
Figure 65. Global Amyloidosis Therapeutics Price (US$/unit) by Type (2020-2031)
Figure 66. Global Amyloidosis Therapeutics Sales Market Share by Application (2020-2031)
Figure 67. Global Amyloidosis Therapeutics Revenue Market Share by Application (2020-2031)
Figure 68. Global Amyloidosis Therapeutics Price (US$/unit) by Application (2020-2031)
Figure 69. Amyloidosis Therapeutics Value Chain
Figure 70. Amyloidosis Therapeutics Production Mode & Process
Figure 71. Direct Comparison with Distribution Share
Figure 72. Distributors Profiles
Figure 73. Amyloidosis Therapeutics Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.